drugset / Trial / NCT01083732

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

NCT01083732

Phase 2 Completed 18 enrolled Boehringer Ingelheim
NaSingle-groupOpen-label

Summary

To investigate the safety and tolerability of dabigatran etexilate solution in children and to obtain preliminary pharmacokinetic/pharmacodynamic data

Timeline

Start
2010-03
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown Oral